Last reviewed · How we verify
Efficacy of Botox intramuscularly at Week 6
Efficacy of Botox intramuscularly at Week 6 is a Small molecule drug developed by ASIS Corporation. It is currently in Phase 1 development. Also known as: Botox (onabotulinumtoxinA).
At a glance
| Generic name | Efficacy of Botox intramuscularly at Week 6 |
|---|---|
| Also known as | Botox (onabotulinumtoxinA) |
| Sponsor | ASIS Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Efficacy of Botox intramuscularly at Week 6 CI brief — competitive landscape report
- Efficacy of Botox intramuscularly at Week 6 updates RSS · CI watch RSS
- ASIS Corporation portfolio CI
Frequently asked questions about Efficacy of Botox intramuscularly at Week 6
What is Efficacy of Botox intramuscularly at Week 6?
Efficacy of Botox intramuscularly at Week 6 is a Small molecule drug developed by ASIS Corporation.
Who makes Efficacy of Botox intramuscularly at Week 6?
Efficacy of Botox intramuscularly at Week 6 is developed by ASIS Corporation (see full ASIS Corporation pipeline at /company/asis-corporation).
Is Efficacy of Botox intramuscularly at Week 6 also known as anything else?
Efficacy of Botox intramuscularly at Week 6 is also known as Botox (onabotulinumtoxinA).
What development phase is Efficacy of Botox intramuscularly at Week 6 in?
Efficacy of Botox intramuscularly at Week 6 is in Phase 1.
Related
- Manufacturer: ASIS Corporation — full pipeline
- Also known as: Botox (onabotulinumtoxinA)
- Compare: Efficacy of Botox intramuscularly at Week 6 vs similar drugs
- Pricing: Efficacy of Botox intramuscularly at Week 6 cost, discount & access